Helal v

Origin: human, cervical carcinoma, subline of Hela.

Cancer Res. 1952. 12: 264; J Exp. Med. 1953. 97: 695; Obstet Gynecol. 1971.38: 945;

 Science 1976. 191: 392; Tissue Antigens. 1978. 11:279, 287.

Morphology: epithelial-like

Mode of cultivation: monolayer

Conditions for cultivation: medium - 199 or EMEM

serum - BS 10% (199) or FBS 10% (EMEM)

other components - NEAA 2% (EMEM)

subculture procedure - cells detach from flask using EDTA 0.02%

with 0.1 mg/ml chimopsin, split ratio 1:5-1:10, optimal population density 0.5-1.0105 cells/cm2

cryoconservation - medium 199 70% + BS 20% or EMEM 70% + FBS 20%,

glycerol 10%, 5.0106 cells/ml in ampule

Viability after cryoconservation: 78-80% (0 passage, dye trypan blue)

Sterility: tests for bacteria, fungi and mycoplasma were negative

Species: karyological and isoenzymological (LDH, G6PD) analysis

Karyology: 2n= 46, variability in the range between 54-83 chromosomes,

modal number of chromosomes 64, number of markers - 14 (3 - specific for Hela - N 1, 2, 3, G-banding)

Tumorigenicity: tumorigenic

Other properties:

virus susceptibility: polioviruses; adenoviruses; Coxsackie; ECHO; vaccinia;

reoviruses; rhinoviruses; arboviruses; measles; RSV.

Isoenzymes G6PD, A.

HLA cell line phenotype (3,28), (w35, w15), C (w2,w3), Ek-1, Ek-7a.

Applications: virology, tumorigenicity.

Collections: MWIIW.

Up